Evidence map›Paper›PMID 29341491›Full record

Trial reportCancer medicine2018

Clinical outcomes of carbon ion radiotherapy with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma in a phase 1/2 clinical trial (Protocol 1001).

Noriyuki Okonogi, Masaru Wakatsuki, Shingo Kato, Kumiko Karasawa, Hiroki Kiyohara, Shintaro Shiba, Daijiro Kobayashi, Takashi Nakano, Tadashi Kamada, Makio Shozu and 1 more

Open access · goldAbstract readClinical Trial, Phase IClinical Trial, Phase II
In one paragraph

Trial report in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Frontiers in oncology · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 1 country.

Noriyuki OkonogiNational Institute of Radiological Sciences Hospital, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.ORCID 0000-0002-9486-1922
Masaru WakatsukiDepartment of Radiology, Jichi Medical University, Tochigi, Japan.
Shingo KatoDepartment of Radiation Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
Kumiko KarasawaDepartment of Radiation Oncology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan.
Hiroki KiyoharaDepartment of Radiation Oncology, Maebashi Red Cross Hospital, Gunma, Japan.
Shintaro ShibaDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Daijiro KobayashiDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Takashi NakanoDepartment of Radiation Oncology, Gunma University Graduate School of Medicine, Gunma, Japan.
Tadashi KamadaNational Institute of Radiological Sciences Hospital, National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan.
Makio ShozuDepartment of Reproductive Medicine, Chiba University Graduate School of Medicine, Chiba, Japan.
Working Group of Gynecological Tumors
Gunma University · JPNational Institutes for Quantum Science and Technology · JPChiba University · JPJichi Medical University · JPMaebashi Red Cross Hospital · JPSaitama International Medical Center · JPTokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We conducted a phase 1/2 study to evaluate the efficacy and safety of carbon ion radiotherapy (C-ion RT) with concurrent chemotherapy for locally advanced uterine cervical adenocarcinoma. Thirty-three patients were enrolled between April 2010 and March 2014. Treatment consisted of C-ion RT with concurrent weekly cisplatin at a dose of 40 mg/m

Indexed as

ChemoradiotherapyHeavy Ion RadiotherapyAdenocarcinoma, Clear CellAdenocarcinoma, MucinousAdultAgedAntineoplastic AgentsCarcinoma, AdenosquamousCisplatinEndometrial NeoplasmsFemaleFollow-Up StudiesHumansMaximum Tolerated DoseMiddle AgedNeoplasm StagingAntineoplastic AgentsCisplatinAdenocarcinomacarbon ion radiotherapycisplatinconcurrent chemoradiotherapyuterine cervical cancer

Identifiers

PMID29341491
PMCPMC5806111
OpenAlexW2793430029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.